|
🐜
|
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
35 auth.
J. Smolen,
M. Schoels,
Norihiro Nishimoto,
F. C. Breedveld,
G. Burmester,
M. Dougados,
P. Emery,
G. Ferraccioli,
C. Gabay,
A. Gibofsky,
J. Gómez-Reino,
Graeme Jones,
T. Kvien,
M. Murakami,
N. Betteridge,
...
Clifton O Bingham,
V. Bykerk,
Ernest Choy,
B. Combe,
Maurizio Cutolo,
W. Graninger,
Angel Lanas,
Emilio Martín-Mola,
C. Montecucco,
Mikkel Ostergaard,
K. Pavelka,
A. Rubbert-Roth,
Naveed Sattar,
M. Scholte-Voshaar,
Yoshiya Tanaka,
Michael Trauner,
Gabriele Valentini,
Kevin L Winthrop,
M. de Wit,
D. M. van der Heijde
|
13 |
2012 |
13
🐜
|
|
🐜
|
US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary
21 auth.
A. Floto,
Kenneth N. Olivier,
L. Saiman,
Charles L. Daley,
J. Herrmann,
Jerry A. Nick,
P. Noone,
D. Bilton,
P. Corris,
Ronald L Gibson,
...
Sarah E Hempstead,
K. Koetz,
Kathryn A. Sabadosa,
I. Sermet-Gaudelus,
Alan R Smyth,
J. Ingen,
Richard J Wallace,
Kevin L Winthrop,
Bruce C Marshall,
C. Haworth,
Cambridge
|
8 |
2015 |
8
🐜
|
|
🐜
|
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update
36 auth.
L. Gossec,
A. Kerschbaumer,
R. Ferreira,
D. Aletaha,
X. Baraliakos,
H. Bertheussen,
W-H. Boehncke,
B. Esbensen,
I. McInnes,
Dennis McGonagle,
Kevin L Winthrop,
A. Balanescu,
Peter V. Balint,
Gerd R Burmester,
Juan D Cañete,
...
P. Claudepierre,
L. Eder,
M. Hetland,
A. Iagnocco,
L. E. Kristensen,
R. Lories,
R. Queiró,
D. Mauro,
H. Marzo-Ortega,
P. Mease,
Peter Nash,
Wendy Wagenaar,
Laura Savage,
G. Schett,
Stephanie J. W. Shoop‐Worrall,
Yoshiya Tanaka,
Filip E Van den Bosch,
A. H. M. van der Helm-van Mil,
A. Zabotti,
D. van der Heijde,
J. Smolen
|
6 |
2024 |
6
🐜
|
|
🐜
|
Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis
14 auth.
A. Kerschbaumer,
J. Smolen,
R. Ferreira,
H. Bertheussen,
X. Baraliakos,
D. Aletaha,
Dennis McGonagle,
D. van der Heijde,
I. McInnes,
B. Esbensen,
...
Kevin L Winthrop,
W. Boehncke,
J. Schoones,
L. Gossec
|
4 |
2024 |
4
🐜
|
|
🐜
|
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
12 auth.
Gerd R Burmester,
J. Gottenberg,
R. Caporali,
Kevin L Winthrop,
Yoshiya Tanaka,
E. V. Ekoka Omoruyi,
...
V. Rajendran,
P. Van Hoek,
K. Van Beneden,
Tsutomu Takeuchi,
René Westhovens,
D. Aletaha
|
2 |
2024 |
2
🐜
|
|
🐢
|
Editorial for the theme issue on Mycobacterium abscessus "all you want to know about Mycobacterium abscessus".
Emmanuelle Cambau,
Giovanni Delogu,
J. van Ingen,
Jean-Louis Herrmann,
Kevin L Winthrop
|
2 |
2024 |
2
🐢
|
|
🐜
|
Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a single-centre, randomised, double-blind, placebo-controlled trial.
8 auth.
Jin Kyun Park,
Miriam Kim,
Ji In Jung,
Ju Yeon Kim,
Heejin Jeong,
Jun Won Park,
...
Kevin L Winthrop,
Eun Bong Lee
|
1 |
2024 |
1
🐜
|
|
🐢
|
What rheumatologists need to know about mRNA vaccines: current status and future of mRNA vaccines in autoimmune inflammatory rheumatic diseases
Jin Kyun Park,
E. Lee,
Kevin L Winthrop
|
1 |
2024 |
1
🐢
|
